Sagent Pharmaceuticals (NAS: SGNT) reported earnings on Feb. 14. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Sagent Pharmaceuticals met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share expanded to zero.
Margins increased across the board.
Sagent Pharmaceuticals notched revenue of $53.2 million. The eight analysts polled by S&P Capital IQ predicted a top line of $53.1 million on the same basis. GAAP reported sales were 9.7% higher than the prior-year quarter's $48.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.00. The nine earnings estimates compiled by S&P Capital IQ anticipated -$0.19 per share. GAAP EPS dropped to zero from the prior-year quarter's -$0.33.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 21.8%, 1,250 basis points better than the prior-year quarter. Operating margin was -1.5%, 1,180 basis points better than the prior-year quarter. Net margin was -0.1%, 1,870 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $57.8 million. On the bottom line, the average EPS estimate is -$0.04.
Next year's average estimate for revenue is $242.7 million. The average EPS estimate is $0.09.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sagent Pharmaceuticals is hold, with an average price target of $19.44.
Add Sagent Pharmaceuticals to My Watchlist.
The article Sagent Pharmaceuticals Beats Up on Analysts Yet Again originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.